top of page

Same-day shipping before 2 PM EST ✦ Janoshik-verified COA ✦ Free shipping over $200 ✦

Durham Peptides Canadian peptide supplier logo

Same-day shipping before 2 PM EST ✦ Janoshik-verified COA ✦ Free shipping over $200 ✦

What Is DSIP? A Research Overview of Delta Sleep-Inducing Peptide

  • Writer: Durham Peptides
    Durham Peptides
  • May 2
  • 8 min read
DSIP delta sleep-inducing peptide research Durham Peptides Canada Delta Sleep-Inducing Peptide (DSIP) occupies an unusual corner of the peptide research field. Discovered in the 1970s during sleep research, DSIP has accumulated decades of published literature without becoming a mainstream research peptide in the way that BPC-157, GHK-Cu, or the metabolic peptides have. The compound's research history spans neuropeptide biology, sleep architecture research, stress response studies, and various other neural research areas — making it a peptide that's well-known in specialized research circles but less widely understood than its longevity and accumulated literature would suggest. This article provides a research-focused overview of DSIP — its discovery, the neuropeptide biology that defines its mechanism, the published research history, and the Canadian regulatory context. Note: DSIP is not currently in the Durham Peptides catalog. This article is informational coverage of published research literature for Canadian researchers following the broader peptide field. The current Durham Peptides catalog includes BPC-157, TB-500, GHK-Cu, MOTS-c, semaglutide, tirzepatide, and retatrutide. The Discovery: 1970s Sleep Research DSIP was first identified in 1977 by Swiss researchers Marcel Monnier and colleagues. The discovery came from research investigating substances that might mediate sleep states. Researchers worked with cerebral venous blood from rabbits during electrically induced "delta sleep" — the deep, slow-wave phase of sleep characterized by delta brain waves. From this blood, they isolated a small peptide that, when administered to other animals, appeared to influence sleep patterns. The compound was named for its association with delta sleep observed in those original experiments, and the abbreviation "DSIP" became standard in the subsequent research literature. The discovery represented a meaningful moment in neuropeptide research — it was one of the early examples of identifying peptides that might function as neurotransmitters or neuromodulators in the central nervous system, separate from the better-characterized neurotransmitters like dopamine, serotonin, and acetylcholine. DSIP Structure and Manufacturing DSIP is a relatively short peptide — nine amino acids in its most-studied form. The structure can be produced via Solid-Phase Peptide Synthesis (SPPS) using synthetic amino acids, the modern standard for research peptide manufacturing. See Peptide Manufacturing 101: How Research Peptides Are Made From Amino Acids to Vial. The relatively simple structure means manufacturing is less complex than for modified peptides like the GLP-1 agonists with fatty acid conjugation. Quality control follows the standard research-peptide framework: HPLC purity verification, mass spectrometry identity confirmation, third-party testing. The Mechanism: Still Being Characterized Despite decades of research since its discovery, the precise mechanism of DSIP remains less well-characterized than for many other research peptides. The published literature has investigated several aspects: Distribution in the central nervous system. DSIP has been detected in various brain regions in research populations, suggesting endogenous biological activity beyond the original sleep context. Receptor pathway uncertainty. Unlike peptides with well-defined receptor systems (like the melanocortin peptides at MC1R-MC5R, or the metabolic peptides at GLP-1/GIP/glucagon receptors), DSIP's specific receptor pathway has been less definitively characterized. Multiple research approaches have explored the question without producing a single dominant model. Investigated biological effects. Published research has investigated DSIP's effects on: Sleep architecture (the original research context) Stress response and cortisol regulation Endocrine system effects Neural protective effects in various model systems Pain perception research Various other neural and physiological research questions The breadth of investigated effects is partly what makes DSIP unusual — most research peptides have a relatively focused mechanism, while DSIP's biological role appears more diffuse and less well-characterized. Pharmacokinetics DSIP's pharmacokinetic profile shares features with other native short peptides: Short half-life. Like many native unmodified peptides, DSIP has a relatively short plasma half-life. This is consistent with the broader pattern of unmodified peptides being subject to enzymatic degradation. For more on why short half-lives can be biologically appropriate rather than a limitation, see Peptide Half-Life Explained: Why Some Peptides Last Hours and Others Days. Blood-brain barrier considerations. DSIP's research history involves substantial work on whether and how the peptide accesses the central nervous system from peripheral administration. The published literature includes various studies on this question with somewhat mixed conclusions. Investigation through multiple administration routes. Sleep peptide research has historically investigated DSIP through various administration routes in research populations. Position in the Broader Peptide Research Field DSIP occupies a distinct position relative to other research peptide categories: Different from metabolic peptides. Semaglutide, tirzepatide, and retatrutide work through incretin receptors — a well-defined receptor system. DSIP's mechanism is less defined. Different from tissue-repair peptides. BPC-157 and TB-500 work through tissue-localized angiogenic and cell migration pathways. DSIP's research focus is in the central nervous system. Different from anti-aging peptides. GHK-Cu and MOTS-c work through gene expression and mitochondrial pathways. DSIP's mechanisms are different. Different from growth hormone peptides. Sermorelin, CJC-1295, and ipamorelin work through the hypothalamic-pituitary GH axis. DSIP's research context is broader and less specifically tied to GH biology, though some overlapping interest exists. See Sermorelin, CJC-1295, and Ipamorelin: A Research Overview of Growth Hormone Peptides. Different from melanocortin peptides. PT-141 works through the melanocortin receptor system. DSIP's central nervous system research is in a different neural framework. The Sleep Peptide Research Category The broader category of sleep-related peptide research includes several research threads: Endogenous neuropeptides associated with sleep. Various peptides have been identified in connection with sleep regulation in published research, with DSIP being one of the earlier-identified examples. Orexin/hypocretin peptides. A more recently characterized peptide system involved in wakefulness regulation. The orexin/hypocretin pathway has substantial research literature in sleep and wakefulness biology. Melatonin and related peptides. Hormonal and peptide messengers involved in circadian rhythm regulation. Adenosine and related signaling. Non-peptide molecules with sleep-related research roles. DSIP's specific position within this broader landscape reflects its early discovery and the subsequent decades of research that haven't fully consolidated around a single mechanistic model. Regulatory Status in Canada DSIP is not approved by Health Canada for human or veterinary therapeutic use. The compound exists in the research peptide framework — sold for laboratory and research applications under research-use-only framing. DSIP is not currently in the Durham Peptides catalog. This article is informational coverage of published research literature. For the broader Canadian regulatory framework, see Are Peptides Legal in Canada? A Complete Guide to Research Peptide Laws. Quality Control Considerations For any DSIP research, the standard quality control framework applies: Identity verification. Mass spectrometry should confirm the compound matches DSIP's expected molecular weight, distinguishing it from related peptides or fragments. Purity verification. ≥99% HPLC purity is the research-grade standard. See Peptide Purity: Why 99% Matters. Storage. DSIP, like other lyophilized research peptides, requires standard refrigerated or frozen storage. Reconstituted with bacteriostatic water, shelf life follows the typical research peptide shelf life under refrigeration. See Peptide Storage & Shelf Life: How to Store BPC-157, Tirzepatide, and Other Research Peptides. Third-party verification. Independent COA via Janoshik Analytical or similar third-party testing remains the research-grade standard. See How to Verify Peptide Quality: COAs, Third-Party Testing & What to Look For. The Research Context: Why DSIP Matters Despite the Mechanism Uncertainty DSIP's continued presence in the research peptide field, despite incomplete mechanism characterization, reflects several features: Long research history. Decades of published literature provide substantive context, even if no single mechanistic model has consolidated. Diverse investigated effects. The breadth of biological systems where DSIP has been studied makes it a useful research tool for various neural and physiological research questions. Established manufacturing. Modern SPPS manufacturing produces consistent DSIP for research applications. Connection to fundamental neuropeptide biology. DSIP's discovery contributed to the broader recognition that peptides function as neural signaling molecules — a foundational concept that continues to develop in current research. Frequently Asked Questions What is DSIP? Delta Sleep-Inducing Peptide. A nine-amino-acid peptide first identified in 1977 from research on substances that might influence delta sleep. Subsequently studied in various neural and physiological research contexts. Who discovered DSIP? Marcel Monnier and Swiss research colleagues, in 1977. The discovery came from work with cerebral venous blood during electrically induced delta sleep in research populations. What does DSIP do in research? The published literature has investigated DSIP's effects on sleep architecture, stress response and cortisol regulation, endocrine system effects, neural protection in various models, and various other neural and physiological research questions. The breadth of investigated effects is unusual. Does Durham Peptides sell DSIP? No. DSIP is not currently in the Durham Peptides catalog. This article is informational coverage of published research literature. Is DSIP FDA-approved? DSIP is not approved by FDA for therapeutic indications and is not approved by Health Canada for therapeutic use. It exists in the research peptide framework. How is DSIP made? Modern DSIP is produced via Solid-Phase Peptide Synthesis (SPPS) using synthetic amino acids — the modern standard for research peptide manufacturing. See Peptide Manufacturing 101. What's DSIP's mechanism? The specific receptor pathway for DSIP has not been definitively characterized in the published research literature. Multiple research approaches have explored the question without producing a single dominant mechanistic model. The compound's biological effects appear more diffuse than peptides with well-defined receptor systems. How does DSIP relate to other sleep research? DSIP is one of several peptides studied in connection with sleep biology in the broader research literature. Other research threads include orexin/hypocretin peptides, melatonin and related signaling molecules, and adenosine-related pathways. What's DSIP's half-life? Short, consistent with other native unmodified peptides subject to enzymatic degradation. See Peptide Half-Life Explained. Is DSIP vegan? Yes, when manufactured via Solid-Phase Peptide Synthesis with synthetic amino acids — the modern standard. See Vegan Peptides. Can I buy DSIP in Canada? DSIP is not currently in the Durham Peptides catalog. Researchers interested in this compound should evaluate available suppliers using the standard six-criteria framework — see Peptides for Sale in Canada. Why isn't DSIP more widely known? Despite its decades of research history, DSIP hasn't reached the mainstream visibility of peptides like BPC-157 or the metabolic peptides. The incomplete mechanism characterization, the diffuse biological effects, and the focus on specialized neural research contexts have kept DSIP in a more specialized research niche. Final Thoughts DSIP represents a distinct corner of the peptide research field — a long-studied neuropeptide with substantial published literature but less consolidated mechanism understanding than many other research peptide categories. The compound's continued research relevance reflects the breadth of biological systems where it has been investigated and its connection to fundamental neuropeptide biology. For Canadian researchers following the broader peptide research field, DSIP and the sleep-related peptide research category warrant attention as part of the broader landscape, even though the compound is not currently in the Durham Peptides catalog. Durham Peptides' current catalog focuses on the metabolic peptide category (semaglutide, tirzepatide, retatrutide), tissue-repair peptides (BPC-157, TB-500), anti-aging peptides (GHK-Cu, MOTS-c), and combination formulations (Wolverine Stack, GLOW Blend) — see the complete catalog at durhampeptides.ca/category/all-products. For continued reading on the broader peptide research field, see Peptide Research Trends 2026: What's Emerging in the Field, What Is Cagrilintide?, Sermorelin, CJC-1295, and Ipamorelin: A Research Overview of Growth Hormone Peptides, What Is PT-141?, and The Complete Peptide Glossary. Selected Research References Monnier M, Schoenenberger GA. Characterization, Sequence, Synthesis and Specificity of a Delta Sleep Inducing Peptide. Sleep 1976: Memory, Environment, Epilepsy, Sleep Staging. 1977. The original discovery paper. Schoenenberger GA. Characterization, Properties and Multivariate Functions of Delta-Sleep-Inducing Peptide (DSIP). European Neurology. 1984;23(5):321-345. https://pubmed.ncbi.nlm.nih.gov/6510437/ Graf MV, Kastin AJ. Delta-Sleep-Inducing Peptide (DSIP): An Update. Peptides. 1986;7(6):1165-1187. https://pubmed.ncbi.nlm.nih.gov/3543849/ Kovalzon VM, Strekalova TV. Delta Sleep-Inducing Peptide (DSIP): A Still Unresolved Riddle. Journal of Neurochemistry. 2006;97(2):303-309. https://pubmed.ncbi.nlm.nih.gov/16539666/ Sudakov KV, Umriukhin PE, Rayevsky KS. Delta-Sleep Inducing Peptide and Neuronal Activity After Glutamate Microiontophoresis: The Role of NMDA-Receptors. Pathophysiology. 2004;11(2):81-86. https://pubmed.ncbi.nlm.nih.gov/15364119/ Khvatova EM, Samartzev VN, Zagoskin PP, Prudchenko IA, Mikhaleva II. Delta Sleep Inducing Peptide (DSIP): Effect on Respiration Activity in Rat Brain Mitochondria and Stress Protective Properties under Hyperbaric Hypoxia Conditions. Peptides. 2003;24(2):307-311. https://pubmed.ncbi.nlm.nih.gov/12668217/ All products sold by Durham Peptides are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease. This article is informational coverage of published research literature on a compound not currently stocked by Durham Peptides. Readers seeking medical guidance should consult a licensed healthcare provider.

DSIP delta sleep-inducing peptide research Durham Peptides Canada


Delta Sleep-Inducing Peptide (DSIP) occupies an unusual corner of the peptide research field. Discovered in the 1970s during sleep research, DSIP has accumulated decades of published literature without becoming a mainstream research peptide in the way that BPC-157, GHK-Cu, or the metabolic peptides have. The compound's research history spans neuropeptide biology, sleep architecture research, stress response studies, and various other neural research areas — making it a peptide that's well-known in specialized research circles but less widely understood than its longevity and accumulated literature would suggest.


This article provides a research-focused overview of DSIP — its discovery, the neuropeptide biology that defines its mechanism, the published research history, and the Canadian regulatory context.


Note: DSIP is not currently in the Durham Peptides catalog. This article is informational coverage of published research literature for Canadian researchers following the broader peptide field. The current Durham Peptides catalog includes BPC-157, TB-500, GHK-Cu, MOTS-c, semaglutide, tirzepatide, and retatrutide.


The Discovery: 1970s Sleep Research


DSIP was first identified in 1977 by Swiss researchers Marcel Monnier and colleagues. The discovery came from research investigating substances that might mediate sleep states. Researchers worked with cerebral venous blood from rabbits during electrically induced "delta sleep" — the deep, slow-wave phase of sleep characterized by delta brain waves. From this blood, they isolated a small peptide that, when administered to other animals, appeared to influence sleep patterns.


The compound was named for its association with delta sleep observed in those original experiments, and the abbreviation "DSIP" became standard in the subsequent research literature.


The discovery represented a meaningful moment in neuropeptide research — it was one of the early examples of identifying peptides that might function as neurotransmitters or neuromodulators in the central nervous system, separate from the better-characterized neurotransmitters like dopamine, serotonin, and acetylcholine.


DSIP Structure and Manufacturing


DSIP is a relatively short peptide — nine amino acids in its most-studied form. The structure can be produced via Solid-Phase Peptide Synthesis (SPPS) using synthetic amino acids, the modern standard for research peptide manufacturing. See Peptide Manufacturing 101: How Research Peptides Are Made From Amino Acids to Vial.


The relatively simple structure means manufacturing is less complex than for modified peptides like the GLP-1 agonists with fatty acid conjugation. Quality control follows the standard research-peptide framework: HPLC purity verification, mass spectrometry identity confirmation, third-party testing.


The Mechanism: Still Being Characterized


Despite decades of research since its discovery, the precise mechanism of DSIP remains less well-characterized than for many other research peptides. The published literature has investigated several aspects:


Distribution in the central nervous system. DSIP has been detected in various brain regions in research populations, suggesting endogenous biological activity beyond the original sleep context.


Receptor pathway uncertainty. Unlike peptides with well-defined receptor systems (like the melanocortin peptides at MC1R-MC5R, or the metabolic peptides at GLP-1/GIP/glucagon receptors), DSIP's specific receptor pathway has been less definitively characterized. Multiple research approaches have explored the question without producing a single dominant model.


Investigated biological effects. Published research has investigated DSIP's effects on:

  • Sleep architecture (the original research context)

  • Stress response and cortisol regulation

  • Endocrine system effects

  • Neural protective effects in various model systems

  • Pain perception research

  • Various other neural and physiological research questions


The breadth of investigated effects is partly what makes DSIP unusual — most research peptides have a relatively focused mechanism, while DSIP's biological role appears more diffuse and less well-characterized.


Pharmacokinetics


DSIP's pharmacokinetic profile shares features with other native short peptides:


Short half-life. Like many native unmodified peptides, DSIP has a relatively short plasma half-life. This is consistent with the broader pattern of unmodified peptides being subject to enzymatic degradation. For more on why short half-lives can be biologically appropriate rather than a limitation, see Peptide Half-Life Explained: Why Some Peptides Last Hours and Others Days.


Blood-brain barrier considerations. DSIP's research history involves substantial work on whether and how the peptide accesses the central nervous system from peripheral administration. The published literature includes various studies on this question with somewhat mixed conclusions.


Investigation through multiple administration routes. Sleep peptide research has historically investigated DSIP through various administration routes in research populations.


Position in the Broader Peptide Research Field

DSIP occupies a distinct position relative to other research peptide categories:


Different from metabolic peptides. Semaglutide, tirzepatide, and retatrutide work through incretin receptors — a well-defined receptor system. DSIP's mechanism is less defined.


Different from tissue-repair peptides. BPC-157 and TB-500 work through tissue-localized angiogenic and cell migration pathways. DSIP's research focus is in the central nervous system.


Different from anti-aging peptides. GHK-Cu and MOTS-c work through gene expression and mitochondrial pathways. DSIP's mechanisms are different.


Different from growth hormone peptides. Sermorelin, CJC-1295, and ipamorelin work through the hypothalamic-pituitary GH axis. DSIP's research context is broader and less specifically tied to GH biology, though some overlapping interest exists. See Sermorelin, CJC-1295, and Ipamorelin: A Research Overview of Growth Hormone Peptides.


Different from melanocortin peptides. PT-141 works through the melanocortin receptor system. DSIP's central nervous system research is in a different neural framework.


The Sleep Peptide Research Category

The broader category of sleep-related peptide research includes several research threads:


Endogenous neuropeptides associated with sleep. Various peptides have been identified in connection with sleep regulation in published research, with DSIP being one of the earlier-identified examples.


Orexin/hypocretin peptides. A more recently characterized peptide system involved in wakefulness regulation. The orexin/hypocretin pathway has substantial research literature in sleep and wakefulness biology.


Melatonin and related peptides. Hormonal and peptide messengers involved in circadian rhythm regulation.


Adenosine and related signaling. Non-peptide molecules with sleep-related research roles.

DSIP's specific position within this broader landscape reflects its early discovery and the subsequent decades of research that haven't fully consolidated around a single mechanistic model.


Regulatory Status in Canada


DSIP is not approved by Health Canada for human or veterinary therapeutic use. The compound exists in the research peptide framework — sold for laboratory and research applications under research-use-only framing.


DSIP is not currently in the Durham Peptides catalog. This article is informational coverage of published research literature.

For the broader Canadian regulatory framework, see Are Peptides Legal in Canada? A Complete Guide to Research Peptide Laws.


Quality Control Considerations


For any DSIP research, the standard quality control framework applies:


Identity verification. Mass spectrometry should confirm the compound matches DSIP's expected molecular weight, distinguishing it from related peptides or fragments.


Purity verification. ≥99% HPLC purity is the research-grade standard. See Peptide Purity: Why 99% Matters.


Storage. DSIP, like other lyophilized research peptides, requires standard refrigerated or frozen storage. Reconstituted with bacteriostatic water, shelf life follows the typical research peptide shelf life under refrigeration. See Peptide Storage & Shelf Life: How to Store BPC-157, Tirzepatide, and Other Research Peptides.


Third-party verification. Independent COA via Janoshik Analytical or similar third-party testing remains the research-grade standard. See How to Verify Peptide Quality: COAs, Third-Party Testing & What to Look For.


The Research Context: Why DSIP Matters Despite the Mechanism Uncertainty

DSIP's continued presence in the research peptide field, despite incomplete mechanism characterization, reflects several features:


Long research history. Decades of published literature provide substantive context, even if no single mechanistic model has consolidated.


Diverse investigated effects. The breadth of biological systems where DSIP has been studied makes it a useful research tool for various neural and physiological research questions.


Established manufacturing. Modern SPPS manufacturing produces consistent DSIP for research applications.

Connection to fundamental neuropeptide biology. DSIP's discovery contributed to the broader recognition that peptides function as neural signaling molecules — a foundational concept that continues to develop in current research.


Frequently Asked Questions


What is DSIP? Delta Sleep-Inducing Peptide. A nine-amino-acid peptide first identified in 1977 from research on substances that might influence delta sleep. Subsequently studied in various neural and physiological research contexts.


Who discovered DSIP? Marcel Monnier and Swiss research colleagues, in 1977. The discovery came from work with cerebral venous blood during electrically induced delta sleep in research populations.


What does DSIP do in research? The published literature has investigated DSIP's effects on sleep architecture, stress response and cortisol regulation, endocrine system effects, neural protection in various models, and various other neural and physiological research questions. The breadth of investigated effects is unusual.


Does Durham Peptides sell DSIP? No. DSIP is not currently in the Durham Peptides catalog. This article is informational coverage of published research literature.


Is DSIP FDA-approved? DSIP is not approved by FDA for therapeutic indications and is not approved by Health Canada for therapeutic use. It exists in the research peptide framework.


How is DSIP made? Modern DSIP is produced via Solid-Phase Peptide Synthesis (SPPS) using synthetic amino acids — the modern standard for research peptide manufacturing. See Peptide Manufacturing 101.


What's DSIP's mechanism? The specific receptor pathway for DSIP has not been definitively characterized in the published research literature. Multiple research approaches have explored the question without producing a single dominant mechanistic model. The compound's biological effects appear more diffuse than peptides with well-defined receptor systems.


How does DSIP relate to other sleep research? DSIP is one of several peptides studied in connection with sleep biology in the broader research literature. Other research threads include orexin/hypocretin peptides, melatonin and related signaling molecules, and adenosine-related pathways.


What's DSIP's half-life? Short, consistent with other native unmodified peptides subject to enzymatic degradation. See Peptide Half-Life Explained.


Is DSIP vegan? Yes, when manufactured via Solid-Phase Peptide Synthesis with synthetic amino acids — the modern standard. See Vegan Peptides.


Can I buy DSIP in Canada? DSIP is not currently in the Durham Peptides catalog. Researchers interested in this compound should evaluate available suppliers using the standard six-criteria framework — see Peptides for Sale in Canada.


Why isn't DSIP more widely known? Despite its decades of research history, DSIP hasn't reached the mainstream visibility of peptides like BPC-157 or the metabolic peptides. The incomplete mechanism characterization, the diffuse biological effects, and the focus on specialized neural research contexts have kept DSIP in a more specialized research niche.


Final Thoughts


DSIP represents a distinct corner of the peptide research field — a long-studied neuropeptide with substantial published literature but less consolidated mechanism understanding than many other research peptide categories. The compound's continued research relevance reflects the breadth of biological systems where it has been investigated and its connection to fundamental neuropeptide biology.


For Canadian researchers following the broader peptide research field, DSIP and the sleep-related peptide research category warrant attention as part of the broader landscape, even though the compound is not currently in the Durham Peptides catalog.


Durham Peptides' current catalog focuses on the metabolic peptide category (semaglutide, tirzepatide, retatrutide), tissue-repair peptides (BPC-157, TB-500), anti-aging peptides (GHK-Cu, MOTS-c), and combination formulations (Wolverine Stack, GLOW Blend) — see the complete catalog at durhampeptides.ca/category/all-products.



Selected Research References


  1. Monnier M, Schoenenberger GA. Characterization, Sequence, Synthesis and Specificity of a Delta Sleep Inducing Peptide. Sleep 1976: Memory, Environment, Epilepsy, Sleep Staging. 1977. The original discovery paper.

  2. Schoenenberger GA. Characterization, Properties and Multivariate Functions of Delta-Sleep-Inducing Peptide (DSIP). European Neurology. 1984;23(5):321-345. https://pubmed.ncbi.nlm.nih.gov/6510437/

  3. Graf MV, Kastin AJ. Delta-Sleep-Inducing Peptide (DSIP): An Update. Peptides. 1986;7(6):1165-1187. https://pubmed.ncbi.nlm.nih.gov/3543849/

  4. Kovalzon VM, Strekalova TV. Delta Sleep-Inducing Peptide (DSIP): A Still Unresolved Riddle. Journal of Neurochemistry. 2006;97(2):303-309. https://pubmed.ncbi.nlm.nih.gov/16539666/

  5. Sudakov KV, Umriukhin PE, Rayevsky KS. Delta-Sleep Inducing Peptide and Neuronal Activity After Glutamate Microiontophoresis: The Role of NMDA-Receptors. Pathophysiology. 2004;11(2):81-86. https://pubmed.ncbi.nlm.nih.gov/15364119/

  6. Khvatova EM, Samartzev VN, Zagoskin PP, Prudchenko IA, Mikhaleva II. Delta Sleep Inducing Peptide (DSIP): Effect on Respiration Activity in Rat Brain Mitochondria and Stress Protective Properties under Hyperbaric Hypoxia Conditions. Peptides. 2003;24(2):307-311. https://pubmed.ncbi.nlm.nih.gov/12668217/


All products sold by Durham Peptides are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease. This article is informational coverage of published research literature on a compound not currently stocked by Durham Peptides. Readers seeking medical guidance should consult a licensed healthcare provider.

bottom of page